Propafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
Glenmark Pharmaceuticals is voluntarily recalling Propafenone Hydrochloride Extended-Release Capsules 325mg (Lot #17230767, exp. Mar-25) distributed nationwide due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall (voluntary, firm-initiated) with no reported illnesses or injuries. The hazard is a manufacturing deviation without evidence of actual product harm, making this a precautionary recall that meets the criteria for Moderate severity.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Propafenone Hydrochloride Extended-Release Capsules, USP 325mg in 60-count bottles. The affected product is identified by NDC# 16714-826-01, Lot # 17230767, with an expiration date of March 2025. The recall was initiated on March 13, 2025, and is distributed U.S. Nationwide.
The recall is being conducted due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. Propafenone Hydrochloride is a prescription oral medication used to treat certain cardiac arrhythmias. The product was manufactured by Glenmark Pharmaceuticals Limited in Pithampur, Madhya Pradesh, India, and distributed by Northstar Rx LLC, Memphis, Tennessee.
Patients taking this medication should consult their healthcare provider or pharmacist before discontinuing use or switching to an alternative product. Healthcare providers and pharmacists should not dispense this lot. The FDA has classified this as a Class II recall, which is ongoing.
For more information, consumers and healthcare professionals may contact the FDA or visit the FDA's Drug Recalls page.
The recalled product
- Product
- PROPAFENONE HYDROCHLORIDE (PROPAFENONE HYDROCHLORIDE)
- Brand
- PROPAFENONE HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 17230767
- exp. date Mar-25
UPCs (2)
- 0316714826011
- 0316714827018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · PROPAFENONE HYDROCHLORIDE
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09